1125 pdev qts
BioCentury & Getty Images

Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

Nov 25, 2020 | 11:32 PM GMT

FDA approves Y-mAbs’ Danyelza for neuroblastoma
Shares of Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) were up 17% in after-hours trading Wednesday after FDA granted accelerated approval to Danyelza naxitamab-gqgk

Read the full 619 word article

How to gain access

Continue reading with a
two-week free trial.